Featured Research

from universities, journals, and other organizations

Experimental drug improves muscle strength among male cancer patients

Date:
June 25, 2012
Source:
The Endocrine Society
Summary:
An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results will be presented Sunday at the Endocrine Society's 94th Annual Meeting in Houston.

An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results were presented June 24 at The Endocrine Society's 94th Annual Meeting in Houston.

Related Articles


The medication, called enobosarm, is the first of a new class of drugs known as selective androgen receptor modulators, which are similar to steroids in their growth-enhancing effects but, potentially, have fewer side effects.

Muscle wasting is a significant problem for many cancer patients due to imbalances in body systems caused by the underlying cancer. In addition, this muscle wasting may be related to low testosterone levels, or hypogonadism, which affects approximately 50 percent of men undergoing treatment for late-stage cancer. Muscle wasting can seriously limit mobility, functioning, and quality of life for affected patients.

In this multi-center drug trial, enobosarm significantly improved physical function among patients with low testosterone, as well as normal hormone levels. Among the low testosterone group, physical function improved by 19 percent, while patients with normal hormone measurements increase their functional ability by 13 percent. At the study's start, 60 percent of patients had subnormal testosterone levels, lost more weight, and suffered greater declines in physical functioning than patients with normal hormone concentrations.

"These data provide evidence that enobosarm may play an important role in the management of cancer-related muscle-wasting even in the setting of low testosterone," said study lead author Adrian Dobs, M.D., M.H.S., professor of medicine and oncology, and vice-chair of the Department of Medicine, Faculty Development at Johns Hopkins University Medical School in Baltimore, MD.

The overall study included 159 cancer patients, of which 65 percent were men. Female participants were post-menopausal, and males were >45 years old. Participants had lost on average about 8 percent of their body weight in the six months preceding the study, and had a body mass index, which is a calculation of weight to height, of <35. Additionally, all patients had received a cancer diagnosis, which included one of the following: non-small-cell lung carcinoma, colorectal cancer, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and breast cancer.

This particular study examined a subset of this population, which comprised 93 male patients. Sixty percent of these men had low testosterone levels at the beginning of the trial. Investigators randomly assigned these participants to receive either 1 or 3 milligrams of oral enobosarm or placebo daily for 16 weeks. Since the trial was double-blinded, neither patients nor researchers knew which group was receiving the study drug versus placebo. At the study's beginning and end, investigators assessed patients' physical functioning using a stair-climbing test.

According to Dobs, this study laid the groundwork for ongoing research examining enobosarm's effects on muscle-wasting specifically among lung-cancer patients.

"Enobosarm has the potential to improve physical performance and increase muscle mass, potentially providing lung-cancer patients with improved strength, or physical function, more independence, increased quality of life, better response to chemotherapy and hopefully longer survival," Dobs said.

Previous findings from the larger study comprising male and female patients have been reported, but these data on the subset of male patients with baseline low testosterone are being presented for the first time.


Story Source:

The above story is based on materials provided by The Endocrine Society. Note: Materials may be edited for content and length.


Cite This Page:

The Endocrine Society. "Experimental drug improves muscle strength among male cancer patients." ScienceDaily. ScienceDaily, 25 June 2012. <www.sciencedaily.com/releases/2012/06/120625092249.htm>.
The Endocrine Society. (2012, June 25). Experimental drug improves muscle strength among male cancer patients. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2012/06/120625092249.htm
The Endocrine Society. "Experimental drug improves muscle strength among male cancer patients." ScienceDaily. www.sciencedaily.com/releases/2012/06/120625092249.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Christmas Kissing Good for Health

Christmas Kissing Good for Health

Reuters - Innovations Video Online (Dec. 22, 2014) Scientists in Amsterdam say couples transfer tens of millions of microbes when they kiss, encouraging healthy exposure to bacteria. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Brain-Dwelling Tapeworm Reveals Genetic Secrets

Brain-Dwelling Tapeworm Reveals Genetic Secrets

Reuters - Innovations Video Online (Dec. 22, 2014) Cambridge scientists have unravelled the genetic code of a rare tapeworm that lived inside a patient's brain for at least four year. Researchers hope it will present new opportunities to diagnose and treat this invasive parasite. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins